Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma

Majority of non-Hodgkin lymphoma (NHL) patients who achieve partial response (PR) or stable disease (SD) to CAR T-cell therapy (CAR T) on day +30 progress and only 30% achieve spontaneous complete response (CR). This study is the first to evaluate the role of consolidative radiotherapy (cRT) for res...

Descripción completa

Detalles Bibliográficos
Autores principales: Saifi, Omran, Breen, William G., Lester, Scott C., Rule, William G., Stish, Bradley J., Rosenthal, Allison, Munoz, Javier, Lin, Yi, Bansal, Radhika, Hathcock, Matthew A., Johnston, Patrick B., Ansell, Stephen M., Paludo, Jonas, Khurana, Arushi, Villasboas, Jose C, Wang, Yucai, Iqbal, Madiha, Moustafa, Muhamad Alhaj, Murthy, Hemant S., Kharfan-Dabaja, Mohamed A., Peterson, Jennifer L., Hoppe, Bradford S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Cell Therapy & Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620596/
https://www.ncbi.nlm.nih.gov/pubmed/37317888
http://dx.doi.org/10.3324/haematol.2023.283311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620596/
https://www.ncbi.nlm.nih.gov/pubmed/37317888
http://dx.doi.org/10.3324/haematol.2023.283311

Ejemplares similares